[News] GAS agents limit pazopanib activity in soft-tissue sarcoma

Leggi l'articolo originale


The concomitant administration of pazopanib—a tyrosine kinase inhibitor (TKI) with absorption that is PH-dependent—and gastric acid-suppressive (GAS) agents, such as proton pump inhibitors (PPIs), might limit the absorption and therapeutic benefits of pazopanib in soft-tissue sarcoma, according to a recent study.

Lascia un commento